NEW preclinical authentic "live" virus data from Washington University School of Medicine demonstrated that AstraZeneca's AZD7442 (tixagevimab co-packaged with cilgavimab) retained potent neutralizing activity against the emerging and highly transmissible Omicron SARS-CoV-2 BA.2 subvariant.1. The data also showed that AZD7442 retained activity against Omicron BA.1 and BA.1.1.1.
The study used a transgenic mouse model to evaluate AZD7442 in pre-exposure prophylaxis (prevention) of Covid-19; similar to how AZD7442 was used in the clinic. These were the first in vivo data that evaluated the efficacy of AZD7442 against the Omicron variants versus previous in vitro neutralising activity assays in cultured cells.
Already have an active account? Log in here.
Continue reading with one of these options:
Continue reading with one of these options:
Premium + Digital Edition
Ad-free access
P 80 per month
(billed annually at P 960)
- Unlimited ad-free access to website articles
- Limited offer: Subscribe today and get digital edition access for free (accessible with up to 3 devices)
TRY FREE FOR 14 DAYS
See details
See details
If you have an active account, log in
here
.